Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How? - UroToday
Metastatic prostate cancer remains a life-limiting disease; while we have seen significant advances in systemic approaches which form the backbone of management, no curative paradigm yet exists. Metastasis-directed therapy (MDT) with stereotactic ablative radiotherapy (SABR) has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer. Herein we will review the rationale, potential benefits, and practical considerations associated with this approach.
Oncology (Williston Park, N.Y.). 2019 Oct 28*** epublish ***
Ryan M Phillips, Matthew P Deek, Theodore L Deweese, Phuoc T Tran
PubMed http://www.ncbi.nlm.nih.gov/pubmed/31661149
https://ift.tt/2XBFl8R
Comments
Post a Comment